Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients

Journal of Viral Hepatitis

Volumn 22, Issue 11, 2015, Pages 882-889

  Cure, S ^a   Guerra, Ines ^a   Dusheiko, G ^b  

^a Mapi   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

chronic hepatitis C infection; cost effectiveness analysis; sofosbuvir

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUSTAINED VIRUS RESPONSE; TREATMENT RESPONSE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; GREAT BRITAIN; HEALTH CARE COST; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; SOFOSBUVIR;

EID: 84943818645     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12409     Document Type: Article

References (37)

1. Chen SL, Morgan TR,. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3 (2): 47-52.
2. Public Health England. Hepatitis C in the UK. Public Health England: UK, 2013.
3. Backx M, Lewszuk A, White JR, et al,. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hepat 2014; 21 (3): 208-215.
4. National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C: Guidance 75 and 106, 2010.
5. National Institute for Health and Clinical Excellence. Boceprevir for the treatment of genotype 1 chronic hepatitis C-NICE technology appraisal guidance 253, 2012. Available at: http://www.nice.org.uk/guidance/ta253/resources/guidance-boceprevir-for-the-treatment-of-genotype1-chronic-hepatitisc-pdf (accessed 18 June 2012).
6. National Institute for Health and Clinical Excellence. Telaprevir for the treatment of genotype 1 chronic hepatitis C-NICE technology appraisal guidance 252, 2012. Available at: https://www.nice.org.uk/guidance/ta252 (accessed 18 June 2012).
7. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ,. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 4: 288-292.
8. North CS, Hong BA, Adewuyi SA, et al,. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013; 35 (2): 122-128.
9. Belperio PS, Hwang EW, Thomas IC, Mole LA, Cheung RC, Backus LI,. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11 (8): 1021-1027.
10. EMA. Sovaldi summary of product characteristics (SmPC), 2014. Available at: www.ema.europa.eu (accessed 5 February 2014).
11. EASL. Clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60 (2): 392-420.
12. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N,. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007; 11 (11): 1-224.
13. Hartwell D, Jones J, Baxter L, Shepherd J,. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011; 15 (17): i-xii. 1-210.
14. McEwan P, Ward T, Yuan Y, Kim R, L'italien G,. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013; 58 (1): 54-64.
15. Chen J, Florian J, Carter W, et al,. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144 (7): 1450-1455.
16. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2013.
17. McLauchlan J,. Query of 5000 anonymised patient records performed October 2013. HCV UK Research Database, 2013. Available at: http://www.hcvresearchuk.org/?page=main (accessed October 2013).
18. EASL. Clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 (2): 245-264.
19. Grishchenko M, Grieve RD, Sweeting MJ, et al,. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009; 25 (2): 171-180.
20. Office for National Statistics. Births and deaths in England and Wales, 2011. Available at: http://www.ons.gov.uk/ons/rel/vsob1/birth-summary-tables - england-and-wales/2011 - final-/sb-births-and-deaths-in-england-and-wales - 2011 - final-.html (accessed 18 June 2012).
21. Wright M, Grieve R, Roberts J, Main J, Thomas HC,. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006; 10 (21): 1-113, iii.
22. Younossi ZM, Stepanova M, Henry L, et al,. Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). J Hepatol 2014; 60 (4): 741-747.
23. Brazier J, Roberts J, Deverill M,. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21 (2): 271-292.
24. Gray AM, Rivero-Arias O, Clarke PM,. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006; 26 (1): 18-29.
25. British National Formulary. 2013. Available at: https://www.medicinescomplete.com/ (accessed 19 June 2014).
26. Department of Health. NHS Reference Costs 2012 to 2013. 2013. Available at: https://www.gov.uk/government/collections/nhs-reference-costs (Accessed 19 June 2014).
27. Personal Social Services Unit. Unit Costs of Health and Social Care 2012. 2012. Available at: http://www.pssru.ac.uk/archive/ (accessed 19 June 2014).
28. Gao X, Stephens JM, Carter JA, Haider S, Rustgi VK,. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res 2012; 12 (3): 335-343.
29. Stevenson M, Lloyd-Jones M, Morgan MY, Wong R,. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation. Health Technol Assess 2012; 16 (4): 1-174.
30. Gilead Sciences. Positron, Interim Synoptic Clinical Study Report, GS-US-334-0107, Foster City. 13 A.D. Jan 23.
31. Gilead Sciences. Fusion, Interim Synoptic Clinical Study Report, GS-US-334-0108, Foster City. 2013. Mar 11.
32. Gilead Sciences. Neutrino, Interim Synoptic Clinical Study Report, GS-US-334-0110, Foster City. 2013. Feb 27.
33. Gilead Sciences. Fission, Interim Synoptic Clinical Study Report, P7977-1231, Foster City. 2013. Feb 25
34. Gilead Sciences. Valence, Interim Synoptic Clinical Study Report, Foster City. 2013. Aug 10.
35. EASL. EASL Recommendations on Treatment of Hepatitis C. 2014 Available at: http://www.easl.eu/ (accessed 19 June 2014).
36. Genotype distribution from the PHE genotype surveillance report 2008-2012, page 9. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/337115/HCV-in-the-UK-2014-24-July.pdf (accessed 1 January 2014).
37. Afdhal N,. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y) 2012; 8 (9): 605-607.